The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19
Open accessPublished version of a preprint
Abstract
COVID‐19 is associated with mitochondrial dysfunction and metabolic abnormalities, including the deficiencies in nicotinamide adenine dinucleotide (NAD + ) and glutathione metabolism. Here it is investigated if administration of a mixture of combined metabolic activators (CMAs) consisting of glutathione and NAD+ precursors can restore metabolic function and thus aid the recovery of COVID‐19 patients. CMAs include l ‐serine, N ‐acetyl‐ l ‐cysteine, nicotinamide riboside, and l ‐carnitine tartrate, salt form of l ‐carnitine. Placebo‐controlled, open‐label phase 2 study and double‐blinded phase 3 clinical trials are conducted to investigate the time of symptom‐free recovery on ambulatory patients using CMAs. The results of both studies show that the time to complete recovery is significantly shorter in the CMA group (6.6 vs 9.3 d) in phase 2 and (5.7 vs 9.2 d) in phase 3 trials compared to placebo group. A comprehensive analysis of the plasma metabolome and proteome reveals major metabolic changes. Plasma levels of proteins and metabolites associated with inflammation and antioxidant metabolism are significantly improved in patients treated with CMAs as compared to placebo. The results show that treating patients infected with COVID‐19 with CMAs lead to a more rapid symptom‐free recovery, suggesting a role for such a therapeutic regime in the treatment of infections leading to respiratory problems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, patients treated with CMAs showed significant improvements in plasma levels of several inflammation and antioxidant metabolism-related biomarkers, such as alanine aminotransferase (ALT), lactate dehydrogenase (LDH), creatinine, glucose, and proteins [109].”
From NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health (2023) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CMAs were found to reinforce immune response and regulate amino acid and lipid metabolism.”
From NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health (2023) · cites this paper as [109]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A study showed that combined metabolic activators (CMAs), consisting of NR (1 g), l-carnitine tartrate (3.73 g), N-acetylcysteine (2.55 g), and serine (12.35 g), improved the COVID-19 outcomes.”
From NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health (2023) · cites this paper as [109]
The cited source says what the claim attributes to it.
In the citing paper
“In both a placebo-controlled, open-label phase 2 study and double-blinded phase 3 clinical trials, patients given CMAs had significantly faster complete recovery times compared to the placebo group (6.6 vs 9.3 days and 5.7 vs 9.2 days, respectively).”
From NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health (2023) · cites this paper as [109]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Extrapulmonary manifestations of COVID-19
Gupta, A., Madhavan, M. V., Sehgal, K., Nair, N., Mahajan, S., Sehrawat, T. S., Bikdeli, B., Ahluwalia, N., Ausiello, J. C., Wan, E. Y., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0968-3 · Cited by 3,185
Cytokine release syndrome in severe COVID-19
Moore, J. B., & June, C. H. (2020) · Science · doi:10.1126/science.abb8925 · Cited by 1,912
Zhu, L., She, Z.-G., Cheng, X., Qin, J.-J., Zhang, X.-J., Cai, J., Lei, F., Wang, H., Xie, J., Wang, W., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.04.021 · Cited by 1,602
Self-citationProteomic and Metabolomic Characterization of COVID-19 Patient Sera
Shen, B., Yi, X., Sun, Y., Bi, X., Du, J., Zhang, C., Quan, S., Zhang, F., Sun, R., Qian, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.032 · Cited by 1,514
Self-citationHung, I. F.-N., Lung, K.-C., Tso, E. Y.-K., Liu, R., Chung, T. W.-H., Chu, M.-Y., Ng, Y.-Y., Lo, J., Chan, J., Tam, A. R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31042-4 · Cited by 1,455
Coperchini, F., Chiovato, L., Croce, L., Magri, F., & Rotondi, M. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.05.003 · Cited by 1,288
Bieganowski, P., & Brenner, C. (2004) · Cell · doi:10.1016/s0092-8674(04)00416-7 · Cited by 750
Nicotinamide riboside is uniquely and orally bioavailable in mice and humans
Trammell, S. A. J., Schmidt, M. S., Weidemann, B. J., Redpath, P., Jaksch, F., Dellinger, R. W., Li, Z., Abel, E. D., Migaud, M. E., & Brenner, C. (2016) · Nature Communications · doi:10.1038/ncomms12948 · Cited by 697
Serine is an essential metabolite for effector T cell expansion
Ma, E. H., Bantug, G., Griss, T., Condotta, S., Johnson, R. M., Samborska, B., Mainolfi, N., Suri, V., Guak, H., Balmer, M. L., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.011 · Cited by 657
Research works printed but not linked: 3
- Thomas T., 2020, JCI Insight, 5
- Hundt M. A., 2020, Hepatology
- 10.1038/pr.2013.71 · DOI
Cited by
Drug treatments for covid-19: living systematic review and network meta-analysis
Siemieniuk, R. A., Bartoszko, J. J., Zeraatkar, D., Kum, E., Qasim, A., Díaz Martinez, J. P., Izcovich, A., Rochwerg, B., Lamontagne, F., Han, M. A., et al. (2020) · BMJ · doi:10.1136/bmj.m2980 · Cited by 846
Advances and Utility of the Human Plasma Proteome
Deutsch, E. W., Omenn, G. S., Sun, Z., Maes, M., Pernemalm, M., Palaniappan, K. K., Letunica, N., Vandenbrouck, Y., Brun, V., Tao, S.-C., et al. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00657 · Cited by 246
Pleiotropic effects of mitochondria in aging
Lima, T., Li, T. Y., Mottis, A., & Auwerx, J. (2022) · Nature Aging · doi:10.1038/s43587-022-00191-2 · Cited by 236
Therapeutic application of natural products: NAD+ metabolism as potential target
Guo, C., Huang, Q., Wang, Y., Yao, Y., Li, J., Chen, J., Wu, M., Zhang, Z., Mingyao, E., Qi, H., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154768 · Cited by 127
Self-citationWhat is really known about the effects of nicotinamide riboside supplementation in humans
Damgaard, M. V., & Treebak, J. T. (2023) · Science Advances · doi:10.1126/sciadv.adi4862 · Cited by 111
Metadata
- Authors
- Altay, O., Arif, M., Li, X., Yang, H., Aydın, M., Alkurt, G., Kim, W., Akyol, D., Zhang, C., Dinler‐Doganay, G., Turkez, H., Shoaie, S., Nielsen, J., Borén, J., Olmuscelik, O., Doganay, L., Uhlén, M., & Mardinoglu, A.
- Affiliations
- Science for Life Laboratory KTH—Royal Institute of Technology Stockholm SE‐100 44 Sweden
- Science for Life Laboratory (SE)
- Ümraniye Eğitim ve Araştırma Hastanesi (TR)
- Department of Molecular Biology and Genetics Istanbul Technical University Istanbul 34469 Turkey
- Department of Medical Biology Faculty of Medicine Atatürk University Erzurum 25240 Turkey
- King's College London (GB)
- Chalmers University of Technology (SE)
- Sahlgrenska University Hospital (SE)
- Department of Internal Medicine Istanbul Medipol University Bagcılar Istanbul 34214 Turkey
- Department of Gastroenterology Umraniye Training and Research Hospital University of Health Sciences Istanbul 34766 Turkey
- ORCID
- Venue
- Advanced Science
- Publisher
- Wiley
- Published
- 2021-06-28
- Volume
- 8
- Issue
- 17
- Pages
- e2101222-e2101222
- ISSN
- 2198-3844 (ISSN-L)
- PMC
- PMC8420376
- OpenAlex
- W3174268490
- Cited by
- 88
- References
- 55
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 15 · 2023: 23 · 2022: 23 · 2021: 13
- FWCI
- 6.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Advanced Science (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Chalmers Research (Chalmers University of Technology) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Istanbul Technical University Academic Open Archive (Istanbul Technical University) (submittedVersion)
- Funders
- Knut och Alice Wallenbergs Stiftelse (20120)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- COVID-19 pandemic, glutathione, NAD+ precursors, N-acetylcysteine, nicotinamide riboside, L-serine, plasma metabolome, plasma proteome, inflammation, antioxidant metabolism, metabolic therapy
- MeSH terms
- COVID-19, Adult, Aged, Antioxidants, Double-Blind Method, Female, Humans, Inflammation, Male, Middle Aged, Proteins, Proteome, Metabolome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19. https://app.cochat.ai/papers/10.1002/advs.202101222
- The paper
- Altay, O., Arif, M., Li, X., Yang, H., Aydın, M., Alkurt, G., Kim, W., Akyol, D., Zhang, C., Dinler‐Doganay, G., Turkez, H., Shoaie, S., Nielsen, J., Borén, J., Olmuscelik, O., Doganay, L., Uhlén, M., & Mardinoglu, A. (2021). Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19. Advanced Science. https://doi.org/10.1002/advs.202101222
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.